Trevi Therapeutics Inc (TRVI) Stock Analysis

Trevi Therapeutics Inc (TRVI) is a publicly traded company in the HEALTHCARE sector. It trades at $13.50, carries a market capitalization of $1.98B. This page summarizes the public market data, fundamentals, and frequently asked questions for TRVI, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Trevi Therapeutics Inc currently has a Bullish sentiment score of 0.39.

About Trevi Therapeutics Inc

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing innovative therapies for patients with serious neurology-mediated conditions. The firm's lead product candidate, Haduvio, targets significant unmet medical needs and is currently undergoing clinical trials. With a strong focus on advancing its pipeline and leveraging its expertise in drug development, Trevi Therapeutics is well-positioned to make a meaningful impact ...

GNG Research Analysis

GNG Research scores Trevi Therapeutics Inc (TRVI) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for TRVI.

Frequently Asked Questions

Does TRVI pay dividends?

Trevi Therapeutics Inc (TRVI) does not currently pay a regular dividend.

What is TRVI's market cap?

Trevi Therapeutics Inc (TRVI) has a market capitalization of $1.98B with a current stock price of $13.50.